
https://www.science.org/content/blog-post/floppiness-not-your-friend-who-knew
# Floppiness Is Not Your Friend: Who Knew? (December 2008)

## 1. SUMMARY

This article explains a fundamental principle in medicinal chemistry: constraining flexible drug molecules by forming rings to improve binding affinity to target proteins. The author describes how drug molecules typically have multiple rotatable bonds that allow them to adopt many conformations, but only one conformation may be optimal for binding to a biological target. 

The core mechanism involves reducing conformational entropy—when a floppy molecule binds to its target, it pays an energetic penalty by losing flexibility and becoming more ordered. By pre-organizing the molecule into a ring structure that resembles the binding conformation, this entropic penalty is reduced, potentially leading to dramatic improvements in binding affinity. However, this strategy is high-risk: if the ring-constrained conformation doesn't match the binding mode, the compound becomes inactive. The article notes that entropy considerations are often underappreciated by medicinal chemists, and the kinetic pathway to binding (whether molecules can navigate energy barriers to reach the binding site) receives insufficient attention compared to static binding models.

## 2. HISTORY

The principles described in this 2008 article remain foundational to drug discovery and have been extensively validated and refined over the past decade and a half:

**Conformational restriction through macrocyclization** has become a major strategy in drug development, particularly for "undruggable" targets. This approach gained significant traction in the 2010s and continues to be widely applied.

**Macrocyclic drugs** have achieved notable clinical and commercial success. Key examples include:
- **BTK inhibitor drugs** (e.g., ibrutinib, approved 2013) that employ conformational constraints
- **Hepatitis C protease inhibitors** like grazoprevir and voxilaprevir that use macrocyclic structures  
- **Kinase inhibitors** across multiple therapeutic areas utilize ring constraints to improve selectivity and potency

**Scientific validation and advancement**: The prediction that entropy is underappreciated proved prescient. The 2010s saw extensive research into thermodynamic profiling of drug binding, with numerous studies demonstrating that entropy-enthalpy compensation significantly impacts binding affinity and selectivity. Computational methods have improved but remain challenging—precisely predicting binding kinetics and pathways remains difficult, though molecular dynamics simulations have become more sophisticated and accessible.

**Industry adoption**: The "floppiness reduction" concept is now standard medicinal chemistry practice. Fragment-based drug discovery, which became more prominent post-2008, often incorporates conformational constraint as compounds are elaborated from small fragments to drug candidates.

## 3. PREDICTIONS

- **Prediction that tying molecules into rings works "either really well or not at all"**
  - **Outcome**: ✓ Correct. This principle has been extensively validated in drug discovery. Macrocyclization strategies show binary outcomes—either substantial improvements in potency/selectivity or complete loss of activity, with few intermediate results.

- **Prediction that entropy receives insufficient attention from medicinal chemists**  
  - **Outcome**: ✓ Largely addressed. The 2010s saw increased focus on thermodynamic profiling and isothermal titration calorimetry (ITC) studies to characterize entropy-enthalpy contributions. While not universally adopted, entropy considerations now receive more systematic attention in drug optimization.

- **Prediction that binding pathway/kinetics are underappreciated compared to static binding**
  - **Outcome**: ⚠ Mixed. While the importance of binding kinetics (kon/koff rates) is now better recognized, and some drugs are designed considering residence time, computational prediction of binding pathways remains challenging. Molecular dynamics simulations have improved but are still not routine in drug discovery workflows due to computational complexity.

- **Prediction that computational modeling of binding processes is very difficult**
  - **Outcome**: ✓ Still true. Despite advances in computing power and algorithms, accurately simulating the complete binding process on relevant timescales remains computationally intensive and not routinely predictive. Most computational drug discovery still focuses on static docked poses rather than dynamic binding trajectories.

## 4. INTEREST
Rating: **8/10**

This article correctly identified fundamental drug design principles that have become increasingly important in targeting challenging biological systems, with macrocyclization now being a standard approach for intractable targets in both academic and industrial drug discovery.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20081210-floppiness-not-your-friend-who-knew.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_